BioNxt Solutions Prepares for Human Bioequivalence Study For MS
23.4.2025 03:05:00 CEST | ACCESS Newswire | Press release
VANCOUVER, BC / ACCESS Newswire / April 23, 2025 / BioNxt Solutions Inc. ("BioNxt" or the "Company") (CSE:BNXT)(OTC PINK:BNXTF)(FSE:BXT), a bioscience innovator specializing in advanced drug delivery systems, is pleased to report advanced preparation for its human bioequivalence study for its lead Multiple Sclerosis (MS) treatment.
BioNxt's lead product, BNT23001, is a proprietary sublingual thin-film formulation of Cladribine for the treatment of MS. Preclinical studies, as reported in internal research data and third-party evaluations, have demonstrated high absorption rates and bioequivalence compared to existing oral tablet therapies. The Company has purchased Cladribine active pharmaceutical ingredient which is necessary to complete the technology transfer process with Gen-Plus, its European Contract Research and Development Organization (CRDO), in Munich, Germany. Once commenced, the bioequivalence study is relatively short, scheduled for less than 30 days from start to finish.
The Company plans to make further updates in the coming weeks regarding its bioequivalent study preparation and scheduling, as well integration of its research and development operations with Gen-Plus.
BNT23001 offers a novel approach to MS management by addressing limitations in traditional oral therapies. Its sublingual thin-film format provides:
Convenience: Easy-to-use and portable, ideal for patients with difficulty swallowing or active lifestyles.
Rapid Absorption: Direct delivery through the sublingual mucosa for faster therapeutic action.
Improved Compliance: A patient-friendly alternative designed to enhance adherence to prescribed regimens.
By delivering these advantages, BNT23001 aligns with BioNxt's mission to improve outcomes for patients living with chronic diseases like MS.
About BioNxt Solutions Inc.
BioNxt Solutions Inc. is a bioscience innovator focused on next-generation drug delivery technologies, diagnostic screening systems, and active pharmaceutical ingredient development. The Company's proprietary platforms-Sublingual (Thin-Film), Transdermal (Skin Patch), and Oral (Enteric-Coated Tablets)-target key therapeutic areas, including autoimmune diseases, neurological disorders, and longevity.
With research and development operations in North America and Europe, BioNxt is advancing regulatory approvals and commercialization efforts, primarily focused on European markets. BioNxt is committed to improving healthcare by delivering precise, patient-centric solutions that enhance treatment outcomes worldwide.
BioNxt is listed on the Canadian Securities Exchange: BNXT, OTC Markets: BNXTF and trades in Germany under WKN: A3D1K3. To learn more about BioNxt, please visit www.bionxt.com.
Investor Relations & Media Contact
Hugh Rogers, Co-Founder, CEO and Director
Email: investor.relations@bionxt.com
Phone: +1 778.598.2698
Web: www.bionxt.com
LinkedIn: https://www.linkedin.com/company/bionxt-solutions
Instagram: https://www.instagram.com/bionxt
Cautionary Statement Regarding "Forward-Looking" Information
This press release contains forward-looking statements within the meaning of applicable securities laws, including statements regarding the development, testing, regulatory approval, and commercialization of BioNxt's sublingual drug products, as well as projected milestones, anticipated partnerships, and potential market opportunities. Forward-looking statements are inherently subject to significant risks, uncertainties, and assumptions, many of which are beyond BioNxt's control. Factors that could cause actual results to differ materially include, but are not limited to, delays in regulatory approvals, negative outcomes from clinical trials, changes in market demand, fluctuations in funding availability, or disruptions in supply chains. Readers are cautioned not to place undue reliance on these forward-looking statements, as actual results may differ materially from those expressed or implied. BioNxt undertakes no obligation to update or revise forward-looking statements, except as required by law. Factors that could cause actual results to differ materially from those projected include changes in market demand, regulatory developments, delays in clinical trials, fluctuations in financing availability, supply chain disruptions, and unforeseen competitive pressures.
SOURCE: BioNxt Solutions Inc.
View the original press release on ACCESS Newswire
BioNxt Solutions Inc.
Subscribe to releases from ACCESS Newswire
Subscribe to all the latest releases from ACCESS Newswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from ACCESS Newswire
Affiliate of Pacific Avenue Capital Partners to Acquire Care.com from IAC3.3.2026 01:00:00 CET | Press release
LOS ANGELES, CA / ACCESS Newswire / March 2, 2026 / Pacific Avenue Capital Partners ("Pacific Avenue"), a Los Angeles-headquartered private equity firm focused on corporate carve-outs and other complex transactions in the middle market, today announced that an affiliate of Pacific Avenue has entered into an agreement to acquire Care.com from IAC Inc. (NASDAQ:IAC). Care.com is a leading platform and brand in the growing $400 billion market for family care, anchored by the largest online network of background-checked child and senior caregivers in the U.S. Care.com operates both a scaled consumer marketplace and an enterprise benefits platform. Since 2007, more than 45 million people have turned to Care.com to find child care, senior care, pet care and housekeeping support. Care.com also partners with more than 700 employers, including many of the Fortune 100, to deliver care-related benefits that combine access to the Care.com platform and comprehensive backup care solutions provided in
Stagwell Launches Stagwell Search+: The Industry's First Agentic Platform To Win AI Search2.3.2026 14:30:00 CET | Press release
New media solution enables brands to win discoverability, visibility, positive sentiment, and outcomes across major AI systems NEW YORK, NY AND LONDON, UK / ACCESS Newswire / March 2, 2026 / Stagwell (NASDAQ:STGW), the global challenger network transforming marketing through AI, today announced the global launch of Stagwell Search+, the industry's first agentic platform for AI Search experiences. Built by Assembly, Stagwell's global omnichannel media agency, in partnership with Emberos, the operating system for AI visibility, Stagwell Search+ is a category-defining solution to master the transition from traditional search engines to AI search experiences. As Large Language Models (LLMs) increasingly mediate how people discover, compare, and choose, Stagwell Search+ helps brands optimize not just for clicks and traffic, but for a new era of search where AI guides decisions and the goal is to be chosen. The solution combines an agentic platform with a differentiated framework that improv
Polaris Renewable Energy Announces Approval of SO1 Agreement by PREPA2.3.2026 13:50:00 CET | Press release
TORONTO, ON / ACCESS Newswire / March 2, 2026 / Polaris Renewable Energy Inc. (TSX:PIF) ("Polaris" or the "Company"), is pleased to announce that, at a meeting held on February 19, 2026, the Governing Board of the Puerto Rico Electric Power Authority ("PREPA") approved the Battery Energy Storage System Standard Offer Agreement ("SO1 Agreement"). The Company received formal written notice of approval on February 27, 2026. The execution of the SO1 Agreement between PREPA and Polaris Power US, Inc. ("PPUS"), a wholly owned subsidiary of Polaris, remains subject to the approval of the Financial Oversight & Management Board (FOMB) of Puerto Rico, which constitutes the next required step in the process. The Company remains optimistic that the FOMB review and authorization will progress in a timely manner relative to prior regulatory milestones achieved for this project. The SO1 Agreement forms part of the Puerto Rico Accelerated Storage Addition Program ("ASAP"), a strategic initiative aimed
MEWA Launches the First Saudi Water Week Next April to Shape the Future of the Water Sector Regionally and Globally28.2.2026 12:55:00 CET | Press release
MEWA Launches the First Saudi Water Week Next April RIYADH, SA / ACCESS Newswire / February 28, 2026 / The Ministry of Environment, Water and Agriculture will inaugurate the first Saudi Water Week during the second week of April. This premier national and international forum will convene policymakers, specialists, researchers, private sector entities, and relevant water sector organizations from both within Saudi Arabia and internationally. This initiative underscores the Ministry's sustained commitment to bolstering water security, reinforcing the sustainable governance of water resources, and fostering scientific research and innovation within this critical sector. The Ministry clarified that the Saudi Water Week will feature several specialized events, including the Arab Water Forum and the Second Stakeholders Meeting for the World Water Forum 2027, in addition to detailed presentations of the achievements of the water sector in the Kingdom and other national sectors. The organizati
Assembly Hires Three Industry Leaders in Europe to Accelerate Growth27.2.2026 12:00:00 CET | Press release
Northway, Ayre, and Panchal add senior depth across AI and data strategy, programmatic activation, and client leadership as Assembly scales in Europe LONDON, UK / ACCESS Newswire / February 27, 2026 / Assembly enters 2026 with momentum and the leadership to match. The Stagwell media agency appoints James Northway as EVP, Global Head of AI and Data Strategy; David Ayre as Europe Head of Programmatic; and Bav Panchal as Europe Managing Partner, strengthening its bench across decision intelligence, activation, and client leadership. Assembly is building on its momentum in the region, following the recent Jabra win and the appointment of Bridget Hopkins as CEO of Europe. These strategic hires accelerate Assembly's expansion across Europe as clients push for integrated brand performance solutions that connect data, technology, media, and commerce to drive measurable growth. Assembly is meeting that demand through continued investment in its STAGE AI Experience Engine and Brand Performance P
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom